Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLP-1 receptor agonist (PEG-Loxenatide) for diabetic foot ulcer healing via PI3K/Akt/FoxO1 pathway
ChiCTR2400083620Phase 4Recruiting
- Sponsor
- Tongji Hospital
- Start
- Apr 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4 trial of polyethylene glycol loxenatide in diabetic foot ulcer (DFU) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Tongji Hospital. Primary endpoint: wound area. Started Apr 2024; status: recruiting.
02
Drugs
polyethylene glycol loxenatide
03
Conditions
diabetic foot ulcer (DFU)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400083620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083620.